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Introduction. There are reported associations between vitamin D deﬁciency and breast, prostate, and colon cancer, but the
relationship in thyroid cancer has not been evaluated. Methods. We evaluated serum calcium, creatinine, albumin, and 25-hydroxy
vitamin D (25-OH-D) in 42 thyroid nodule, 45 thyroid cancer in remission, and 24 active thyroid cancer patients. Results. 25-OH-
D was not diﬀerent between groups. The percent with 25-OH-D levels <75nmol/L was not signiﬁcantly diﬀerent between groups
and was not aﬀected by season of measurement, age, or cancer stage. Multivariate regression showed a BMI of ≥30kg/m2 to be the
only signiﬁcant predictor of vitamin D deﬁciency. Conclusions. Rates of vitamin D deﬁciency are similar in thyroid nodules and
thyroid cancer, although higher than the general population. This is diﬀerent than previous studies for other cancers, which show
higher rates of vitamin D deﬁciency. BMI was the only predictor of vitamin D deﬁciency.
1.Introduction
Thyroid cancer is the most common endocrine-related
malignancy.Thyroidcancerismorecommoninfemales,and
iscurrentlytheseventhleadingcauseofnewcancerdiagnosis
in women [1]. These cancers can range from papillary or
follicularthyroid carcinoma, both well-diﬀerentiated tumors
with excellent prognosis and indolent course, to poorly dif-
ferentiated, and often lethal, anaplastic form [2]. Currently,
known risk factors for thyroid cancer include previous high-
dose environmental radioactive iodine exposure, previous
childhood radiation to the head and neck, iodine deﬁciency,
female gender, and family history of thyroid cancer [3, 4].
In 2007, there were estimated 33550 new cases of thyroid
cancer diagnosed, with estimated 1530 total deaths [5]. The
incidence of new thyroid cancer diagnosis has increased by
6.2%from1997to2004,withaconcomitantincreaseinmor-
tality by 0.3% from 1985 to 2004 [1]. It is unknown whether
this rise in thyroid cancer is due to increased imaging of the
neck resulting in increased diagnosis of smaller, nonpalpable
cancers (mainly papillary thyroid carcinoma) that would
have previously gone undiagnosed [6] or whether this is
due to a true rise in thyroid cancer from an undetermined
etiology.
Recently, studies have shown associations between vita-
min D deﬁciency and breast [7], prostate [8], and colon [9]
cancers. However, the association between vitamin D levels
and thyroid cancer is unknown. There are animal models
and in vitro studies that have shown vitamin D to have an
antiproliferative eﬀect on thyroid cancer [10–12].
This study evaluates vitamin D deﬁciency as not only
a potential novel risk factor for thyroid cancer but also a
potential therapeutic target. If thyroid cancer is similar to
other solid tumors regarding its relationship to vitamin D,
we hypothesize that vitamin D levels will be lower in patients
with active thyroid cancer than patients with thyroid cancer
in remission, and that both thyroid cancer groups will be
lower than thyroid nodules.
2.MaterialsandMethods
2.1. Patients. This study was approved by the University of
Nebraska Medical Center IRB to use stored blood specimens
from the Thyroid Cancer Collaborative Registry (TCCR).2 International Journal of Endocrinology
The TCCR was established at UNMC/The Nebraska Medical
Center in March 2008 and has accrued over 300 patients to
date. The TCCR is a thyroid cancer and nodule database reg-
istry and biospecimen bank. All patients who give informed
consent to be a part of the registry complete a standard-
ized questionnaire that contains demographic information,
medical history, family history, diet and lifestyle habits, past
or current environmental exposures, and occupation. Blood
and tissue samples are collected and stored for all patients
with thyroid cancer and thyroid nodules.
This study is a pilot study designed to provide prelim-
inary data, which will allow us to design a larger study. To
design a larger trial, using the outcome “the proportion of
persons with vitamin D deﬁciency” (deﬁned as a baseline
vitamin D level of <75nmol/L), a sample size of 160 subjects
(32 patients with residual disease, 64 patients in remission,
and 64 noncancer controls with thyroid nodules) would
achieve an 80% power to detect an eﬀect size of 0.25 using
2 degrees of freedom Chi-Square Test with a signiﬁcance
level of 0.05. An eﬀect size of 0.25 corresponds to vitamin
D deﬁciency in approximately 32% of controls subjects, 59%
of subjects in remission, and 59% of subjects with residual
disease. Since this is a pilot study, we aimed to accrue 37% of
the sample size of a fully powered study.
We evaluated 24 patients with active thyroid cancer, 45
patients with thyroid cancer in remission, and 42 patients
with thyroid nodules. Patients were eligible if they had a his-
tory of thyroid cancer (papillary, follicular, follicular variant
of papillary, or hurthle cell thyroid cancer), had a thyroid
nodule, and were older than 19 years of age. At the time
of the study, there were no cases of medullary or anaplastic
thyroid cancers in the TCCR. Patients were also excluded
if pregnant, or breast-feeding. Patients with a history of
thyroid cancer were considered to be in remission if they
met one of the following criteria: (1) total thyroidectomy
and radioactive iodine remnant ablation and unstimulated
thyroglobulin <1ng/mL and/or stimulated thyroglobulin
<5ng/mL and >6 months since initial treatment or >12
months since repeat treatment; (2) total thyroidectomy
and no radioactive iodine remnant ablation and negative
neck ultrasound; (3) less than total thyroidectomy and
no radioactive iodine remnant ablation and negative neck
ultrasound; (4) detectable antithyroglobulin antibodies and
negative imaging (radioactive iodine whole body scan or
ultrasound). Patients with a history of thyroid cancer were
considered to have active disease if they met one of the
following criteria: (1) total thyroidectomy and radioactive
iodine remnant ablation and unstimulated thyroglobulin
>1ng/mL and/or stimulated thyroglobulin >5ng/mL; (2)
Less than 6 months from initial treatment or <12 months
from treatment for recurrent or persistent disease; (3)
Evidence of gross recurrence by imaging. Thyroid nodules
were included if they had thyroid nodules conﬁrmed by
ultrasound, regardless of size. Patients with thyroid nodules
were on thyroid hormone replacement if clinically indicated,
but all were not placed on thyroid hormone empirically. All
thyroid cancer patients were on thyroid hormone replace-
ment to suppress TSH as indicated by current thyroid cancer
treatment standards.
2.2. Methods. Demographic information including age, gen-
der, BMI, season of vitamin D measurement was obtained
in addition to histologic type of thyroid cancer, TNM
staging, and vitamin D supplementation history. The chart
was also reviewed for baseline vitamin D measurement in
patients who were taking >800IU vitamin D per day. Stored
serum from the TCCR was assessed for serum calcium,
albumin, creatinine, and 25-hydoxy-vitamin D (25-OH-
D). Serum utilized to run laboratories was obtained from
participants over a period starting 4/1/2008 and ending on
2/6/2009. The serum calcium, albumin, and creatinine were
evaluated at the UNMC/NMC laboratories utilizing Ortho
Clinical Diagnostics Vitros 950 system. For those individuals
taking supplemental vitamin D exceeding 800IU per day,
we utilized baseline 25-OH-D levels prior to vitamin D
supplementation, if available. Baseline 25-OH-D levels were
obtained from the electronic medical record, and extend
from 12/15/2001 through 2/2/2009. However, 25-OH-D
levels prior to 07/22/2008 were sent to ARUP for analysis
that used either DiaSorin or Nichols assays during that
period. All 25-OH-D levels starting 07/23/2008 were done
through the UNMC/NMC laboratories, utilizing tandem
mass spectrometry on the Applied Biosystems API3000
MS/MS equipped with Agilent 1100LC. Baseline 25-OH-D
levels prior to July 2008 (ARUP assays) were obtained from
11 thyroid nodules, 10 thyroid cancer in remission, and 2
active thyroid cancer patients. There were 2 thyroid nodules,
1 thyroid cancer in remission, and 4 active thyroid cancer
patients who did not have baseline 25-OH-D levels available,
or were on an unknown dose of vitamin D, and stored serum
was used to evaluate 25-OH-D levels.
2.3. Analysis. Patient characteristics for each group were
assessed using descriptive statistics, including medians,
range, frequencies, and proportions. Categorical outcomes
were compared between the 3 groups using a Fisher’s exact
test. Continuous outcomes were compared between the
groups using the Kruskal Wallis test with subsequent pair-
wise comparisons performed using a Wilcoxon rank sum
test and a Bonferroni-adjusted alpha level of 0.017 when the
overall test was signiﬁcant. A logistic regression modeling
procedure was used to compare the odds of low 25-OH-
Dl e v e l s( v i t a m i nD<75 versus vitamin D ≥75nmol/L)
between patient groups while adjusting for other risk
factors: gender, age (19–45 years versus >45 years), BMI
(<30 versus >30kg/m2), season of vitamin D measurement
(winter: October–March; summer: April–September), and
TNM staging. Only risk factors signiﬁcant at the 0.10 level in
univariate analysis were included in the multivariate model.
Av a l u eo fP<. 05 was considered signiﬁcant for all other
comparisons.
Tandem mass spec for vitamin D assay was used for all
patients that were not on supplemental vitamin D >800IU
per day. If they were on vitamin D >800IU per day, baseline
vitamin D levels, utilizing either Diaosrin or Nichols assays,
were used in the analysis as described earlier. Because of the
potential for diﬀerences in vitamin D levels obtained with
diﬀerent assays, we also analyzed our data using only the
patients with vitamin D levels assessed by the tandem massInternational Journal of Endocrinology 3
spec method, which included the majority of patients in the
study (81%). We did have a small number of patients (13%)
with samples run on both the Diasorin and mass spec assays
available, so we also compared the mean ± SD of vitamin D
of the 2 assays.
This research was funded by a grant from the University
of Nebraska Medical Center Center for Clinical and Transla-
tional Research.
3. Results andDiscussion
A total of 111 patients were evaluated, 42 (38%) nodules,
45 (40%) thyroid cancer in remission, and 24 (22%) active
thyroid cancer. Baseline characteristics are provided in
Table 1. Gender, age, season, and BMI were not signiﬁcantly
diﬀerent between groups, however, there was a trend toward
more males in the active thyroid cancer group. All patients
enrolled in this study were Caucasian. Ninety percent of the
nodule group was female compared with 87% in remission
and 71% percent in the active thyroid cancer group (P =
.11). Fifty-seven percent of the nodule group was >45 years,
compared with 44% of the remission group and 37% of
the active group (P = .28). Summer season of vitamin D
measurement was 62% in the nodule group, 64% in the
remission group, and 67% in the active group (P = .94).
There was no signiﬁcant diﬀerence between the remission
and active thyroid cancer groups when evaluating for TNM
stage (P = .20) or histologic type of thyroid cancer (P =
.35). Calcium, albumin, and creatinine were not statistically
diﬀerent between groups (data not shown).
After removal of the Diasorin and Nichols assays, a
total of 90 patients were evaluated. This included 33 (37%)
nodules,35(39%)thyroidcancerinremission,and22(24%)
active thyroid cancer patients. Using only the mass spec
vitamin D samples, gender, age, season, and BMI were not
signiﬁcantly diﬀerent. However, TNM stage was signiﬁcantly
diﬀerent between the remission and active cancer groups
showingahigherpercentageoftheremissiongroupwasstage
I. In the remission group, 82% were stage I, 9% were stage II,
3% were stage III, and 6% were stage IVa, while in the active
cancer group, 55% were stage I, 15% were stage II, 22% were
stage III, and 5% were stage IVa (P = .05). Histologic type of
cancer was not signiﬁcantly diﬀerent.
Vitamin D deﬁciency was deﬁned as 25-OH-D
<75nmol/L. When evaluating each group (using all
vitamin D assays) for percentage of patients with vitamin
D deﬁciency, there was no signiﬁcant diﬀerence (Table 2).
Fifty-two percent of thyroid nodules, 44% of thyroid cancer
in remission, and 42% of active thyroid cancer patients were
vitamin D deﬁcient (P = .67). When stratifying each group
by vitamin D tertiles (<25nmol/L versus 25–75nmol/L
versus >75nmol/L), there again was no signiﬁcant diﬀerence
(P = .74) (Table 2). In the nodule versus remission
versus active groups, 2%, 4%, and 0% were <25nmol/L,
respectively. However, 52%, 40%, and 46% had 25-OH-D
levels between 25–75nmol/L, respectively, and 45%, 56%,
and 54% had 25-OH-D levels of >75nmol/L, respectively.
After removing the Diasorin and Nichols assays, there was
still no signiﬁcant diﬀerence when evaluating each group for
percentage of patients with vitamin D deﬁciency or when
stratifying each group by tertiles (Table 2).
Whenevaluating median (range)25-OH-D forthe entire
group (using all vitamin D assays), the summer group (n =
71)hadamedian25-OH-Dof73(<25–180)nmol/L,andthe
wintergroup(n = 40)hadamedianof93(<25–218)nmol/L
(P = .56). In the nodule group, the summer group (n = 26)
had a median of 76.3 (33–165)nmol/L and the winter group
(n = 1 6 )h a dam e d i a no f7 0( <25–128)nmol/L (P = .13).
In the remission group, the summer group (n = 29) had a
median of 65 (<25–180)nmol/L and the winter group (n =
16) had a median of 95 (38–148)nmol/L (P = .14). In the
active group, the summer group (n = 1 6 )h a dam e d i a no f8 0
(30–128)nmol/L and the winter group (n = 8) had a median
of 108 (45–218)nmol/L (P = .20). When evaluating the
distributionintertiles,nosigniﬁcantdiﬀerencewasobserved
(data not shown).
AfterremovalofvitaminDlevelsobtainedfromDiasorin
and Nichols assays, there was no signiﬁcant diﬀerence when
evaluating the median (range) 25-OH-D of the entire group,
or any of the groups individually. In the group as a whole,
the summer group (n = 63) had a median 25-OH-D of
80 (<25–180)nmol/L, and the winter group (n = 40) had
a median of 93 (25–218)nmol/L (P = .28). In the nodule
group, the summer group (n = 24) had a median of 88 (33–
165)nmol/L and the winter group (n = 9) had a median
of 73 (25–128)nmol/L (P = .18). In the remission group,
the summer group (n = 24) had a median of 68.8 (<25–
180)nmol/L and the winter group (n = 11) had a median
of 98 (38–148)nmol/L (P = .10). In the active group, the
summergroup(n = 15)hadamedianof85(30–128)nmol/L
and the winter group (n = 7) had a median of 120 (48–
218)nmol/L (P = .10). When evaluating the distribution
in tertiles, no signiﬁcant diﬀerence was observed (data not
shown).
Cancer stage and vitamin D levels were not statistically
diﬀerent (Table 3). In the remission group, stage I had a
median (range) 25-OH-D of 84 (<25–180)nmol/L, stage II
had a median of 60 (45–158)nmol/L, stage III had a median
of 93 (38–135)nmol/L, and stage IVa had a median of 93
(65–118)nmol/L (P = .92). In the active group, stage I had
a median 25-OH-D of 84 (30–218)nmol/L, stage II had a
median of 95 (85–108)nmol/L, stage III had a median of
80 (48–88)nmol/L, and stage IVa had a median of 95 (45–
95)nmol/L (P = .71). After removing the vitamin D levels
obtained from Diasorin and Nichols assays, no statistical
diﬀerence was observed when evaluating cancer stage and
vitamin D levels (Table 3).
Vitamin D levels in diﬀerent histologic types of thyroid
cancer were also not statistically diﬀerent (Table 4), however
there was a trend for papillary thyroid cancer to have
higher median levels of vitamin D compared with other
histologic types of thyroid cancer (using all vitamin D
assays). Median (range) 25-OH-D for papillary thyroid can-
cer was 89 (<25–218)nmol/L and the other histologic types
combined were 60 (38–180)nmol/L (P = .28). The same
ﬁndings were observed when removing vitamin D levels
obtained from Diasorin and Nichols assays from our analysis
(Table 4).4 International Journal of Endocrinology
Table 1: Baseline Characteristics.
Characteristic Nodule (n = 42) Remission (n = 45) Active (n = 24)
Sex Count (%) Count (%) Count (%) P-value
Female 38 (90) 39 (87) 17 (71)
Male 4 (10) 6 (13) 7 (29) .11
Age group
Older (>45years) 24 (57) 20 (44) 9 (37)
Younger (19–45 years) 18 (43) 25 (56) 15 (63) .28
Season
Summer 26 (62) 29 (64) 16 (67)
Winter 16 (38) 16 (36) 8 (33) .94
TNM stage
1 na 31 (74) 12 (55)
2 na 5 (12) 3 (14)
3 na 3 (7) 5 (23)
4A na 3 (7) 1 (5)
4B na 0 1 (5) .20∗
CA pathology
Nodule 42 (100) 0 0
Papillary 0 34 (76) 22 (92)
Follicular 0 4 (9) 1 (4)
Follicular variant of papillary 0 7 (16) 1 (4) .35∗
Race
Caucasian 42 (100) 45 (100) 24 (100)
BMI (kg/m2) Median (range) Median (range) Median (range)
28.0 (19.8–51.7) 27.4 (17.8–43.0) 29.0 (16.7–46.0) .66
∗P-values for TNM stage and CA pathology were based on comparisons between the remission and active cancer groups only.
Table 2: Distribution of vitamin D levels for each group.
All vitamin D assays Nodule (n = 42) Remission (n = 45) Active (n = 24)
Vitamin D group Count (%) Count (%) Count (%) P-v a l u e
<25nmol/L 1 (2) 2 (4) 0
25–75nmol/L 22 (52) 18 (40) 11 (46)
>75nmol/L 19 (45) 25 (56) 13 (54) .74
Vitamin D group
<75nmol/L 22 (52) 20 (44) 10 (42)
≥75nmol/L 20 (48) 25 (56) 14 (58) .67
Tandem mass spec assay Nodule (n = 33) Remission (n = 35) Active (n = 22)
Vitamin D group Count (%) Count (%) Count (%) P-v a l u e
<25nmol/L 0 1 (3) 0
25–75nmol/L 17 (52) 14 (40) 9 (41)
>75nmol/L 16 (48) 20 (57) 13 (59) .75
Vitamin D group
<75nmol/L 16 (48) 15 (43) 8 (36)
≥75nmol/L 17 (52) 20 (57) 14 (64) .32
However, BMI >30kg/m2 was the only signiﬁcant risk
factor for vitamin D deﬁciency in univariate analysis (OR
6.98, 95% CI:2.95–16.52, P<. 0001). This held true
when analyzing the data using only tandem mass spec
vitamin D levels (OR 9.33, 95% CI:3.50–24.88, P<. 0001).
Multivariate analysis after adjustment for BMI revealed that
cancer status was not a signiﬁcant predictor for vitamin D
deﬁciency compared to the nodule group. BMI >30kg/m2,
however, remained a statistically signiﬁcant risk factor for
vitamin D deﬁciency (OR 7.13, 95% CI:2.99–17.01, P<
.0001). As BMI was the only signiﬁcant risk factor for
vitamin D deﬁciency, we compared the group as a whole,International Journal of Endocrinology 5
Table 3: Thyroid Cancer Stage and Median 25-OH-D levels.
TNM stage N Median nmol/L Minimum nmol/L Maximum nmol/L P-v a l u e
All vitamin D assays
Remission
13 0 8 4 <25 180
2 5 60 45 158
3 3 93 38 135
4A 3 93 65 118 .92
Active
1 12 84 30 218
2 3 95 85 108
3 5 80 47 88
4A 2 95 45 95 .71
Tandem mass spec vitamin D assays
Remission
12 7 8 8 <25 180
2 3 58 45 158
3 1 93 93 93
4A 2 91.3 65 118 .93
Active
1 11 95 30 218
2 3 95 85 108
3 5 75 48 88
4A 1 95 95 95 .61
Table 4: Histologic Type of Thyroid Cancer and 25-OH-D levels.
Cancer pathology N Median nmol/L Minimum nmol/L Maximum nmol/L P-value
All vitamin D assays
Papillary 56 89 <25 218
Other 13 60 38 180 0.28
Tandem mass spec Vitamin D assay
Papillary 47 88 <25 218
Other 10 73.8 43 180 0.61
and individually. When using all vitamin D specimens,
BMI ≥30kg/m2 was signiﬁcantly associated with vitamin
D deﬁciency in the entire group (P<. 0001), thyroid
nodule group (P = .0001), and active thyroid cancer group
(P = .04), but not the thyroid cancer in remission group
(P = .12). When using only tandem mass spec vitamin
D levels, BMI ≥30kg/m2 was signiﬁcantly associated with
vitamin D deﬁciency in the entire group (P<. 0001), thyroid
nodule group (P = .0004), and thyroid cancer in remission
group (P = .03), but not the active thyroid cancer group
(P = .08).
We had 14 patients who had a clinical sample run using
the Diasorin assay and a stored research sample run later
using mass spec from the same day. We found the mean ±
SD for the mass spec assay of vitamin D level was 94.7 ±
35.8nmol/L, while the Diasorin assay vitamin D level was
84±43.1nmol/L.Themeandiﬀerencebetweenthetwoassays
was 10.5 ± 22nmol/L (95% CI: −2.13–23.18), showing no
signiﬁcant diﬀerence between the assays.
4. Conclusion
This pilot study shows levels of vitamin D and rates of
vitamin D deﬁciency to be similar between patients with
thyroid nodules, thyroid cancer in remission, and active
thyroid cancer. We did not ﬁnd an association between
vitamin D deﬁciency and the histologic type of thyroid
cancer,thestageofthyroidcancer,orthestatusofthedisease.
The only risk factor found to be independently associated
with vitamin D deﬁciency was BMI >30kg/m2, consistent
with previous studies [13, 14].
These results are diﬀerent from other studies that have
shownarelationshipbetweenvitaminDdeﬁciencyandother
solid tumors. One recent study evaluated the incident risk
of developing nonskin cancers of all types when vitamin D
supplementation was administered over four years [15]. This
study compared individuals receiving calcium plus 1000IU
of vitamin D supplementation to calcium supplementation
only and placebo controls. All individuals had similar6 International Journal of Endocrinology
baseline mean 25-OH-D levels around 70nmol/L, with a
mean increase in 25-OH-D levels of 24nmol/L at 12 months
in the group receiving vitamin D only. In comparison to
the placebo group, the calcium plus vitamin D group had a
lower relative risk of developing cancer over the course of the
study. Epidemiological studies have also shown an increased
incidence of colon cancer with lower levels of vitamin D.
VitaminDlevelsinthelowestquartileofvitaminD,orbelow
75nmol/L, have been associated with approximately twice
the risk of colon cancer than those with higher levels [9, 16].
Levels of 25-OH-D in postmenopausal women with breast
cancer have been shown to be lower than women without
breast cancer and there is a signiﬁcant inverse association
between 25-OH-D levels and postmenopausal breast cancer
[7]. Another study evaluating prostate cancer and vitamin D
alsodemonstratedriskwasinverselyrelatedto25-OH-D,but
the risk in this study was only seen at levels <40nmol/L [8].
Using thyroid nodules as noncancer controls, we did not see
a signiﬁcant diﬀerence between the thyroid cancer groups,
active or remission, or the thyroid nodules. This needs to be
investigated further. This could be due to thyroid nodules
not truly being “healthy” controls, and may represent
early thyroid pathology, or early thyroid cancers. It could
also be that thyroid cancer generally has a less aggressive
course as compared with breast, colon, and some forms
of prostate cancer and may not be associated with vitamin
D status.
The only risk factor for vitamin D deﬁciency in our study
w a sB M I ,c o n s i s t e n twi t hp r evi o u ss t u d i e s[ 13, 14]. Season of
vitamin D measurement has previously been shown to aﬀect
vitamin D levels, especially in northern latitudes where there
is no cutaneous conversion of vitamin D in the skin during
the winter months [17, 18]. Our study, however, did not see
am a r k e dd i ﬀerence in the groups in summer versus winter.
One explanation could be that we did not have a summer
and winter sample from each person. Another explanation
c o u l db et h a tv i t a m i nDl e v e l sm a yb el e s sd e p e n d e n to n
cutaneous conversion of vitamin D when associated with
thyroid nodules or cancer. Interestingly, the median levels,
when comparing all groups together, were higher during
the winter months. However, when categorized into tertiles,
the 25–75 and >75nmol/L range had a higher percentage
of individuals from the summer group. Although it is
possible that having more summer specimens could aﬀect
these results, post-hoc analysis did not show a statistically
signiﬁcant eﬀect of season on vitamin D levels.
Previous reports of vitamin D deﬁciency in healthy
populations have been roughly 14–34% [14, 18, 19]. We
overall found higher rates of vitamin D deﬁciency in all three
of our groups. The prevalence of vitamin D deﬁciency in
nodules was 48%, thyroid cancer in remission was 56%, and
active thyroid cancer was 58%. Even though the rates were
not statistically diﬀerent between groups, all three groups
were higher than what has been previously reported in
healthy subjects. Ethnicity has been associated with vitamin
Dl e v e l s[ 20, 21], so it is important to consider when
comparing data. Our study participants were predominantly
Caucasians, so should be compared to normal controls with
similar ethnicity. Recently, NHANES data showed there has
been an overall decline in 25-OH-D levels from the 1988–
1994 census compared with the 2001–2004 census [19].
This could explain the increased rates of overall vitamin
D deﬁciency in all three of our groups, however, there
are many potential reasons for this change, one of which
includes changes and overall improvement in the vitamin
D assay. Other potential causes could be diﬀerence in
ethnicity, season of measurement of vitamin D, and BMI
of the population as a whole. All of these issues need to be
considered when comparing the data.
One of the main limitations of this study is the lack
of healthy (no thyroid disease) controls. Unfortunately,
healthy patients without thyroid disease are not part of the
TCCR database. However, in a separate, published study
[14], healthy controls were recruited and vitamin D levels
obtained at our institution, and we use them as a basis for
comparison since they are demographically similar to our
current study group. In that study, there were 41 healthy
control, nonobese participants with a mean age was 46.3
years.However,Seventy-eightpercentwerefemale,98%were
Caucasian, and they had a mean BMI of 24.7kg/m2. That
group is also representative of our study group because it
represents patients from the same latitude, and included
vitaminDlevelsfrombothsummer(54%)andwinter(46%)
months. The prevalence of vitamin D deﬁciency in that
healthy control population was 32% [14]a sc o m p a r e dw i t h
our data showing 48% of thyroid nodules with vitamin D
deﬁciency and 56–58% of thyroid cancer.
Another limitation is the small sample size. As this
is a pilot study, our numbers are small, which may have
prevented us from detecting a statistical diﬀerence. Our
results, therefore, will need to be conﬁrmed with a larger,
potentially multicenter study. It is important to consider
that some autoimmune conditions have been reported to
be associated with vitamin D deﬁciency, which may play a
role in our thyroid nodule group. Thyroid antibodies are not
routinely obtained for all thyroid nodule patients, so were
not available from all patients. However, when evaluating
those patients that did have antibodies available, there was
only 14% of the entire group that had positive antibodies.
We recognize that using diﬀerent vitamin D assays may
result in diﬀerent vitamin D levels reported. To account for
this potential diﬀerence, we have analyzed our data using
results combined from the three diﬀerent assays, as well as
tandem mass spec alone, which make up the majority of
specimens (81%). We did not ﬁnd any signiﬁcant diﬀerences
in our results when analyzing data from the whole group and
mass spec assay only, and there was no signiﬁcant diﬀerence
between vitamin D levels when comparing simultaneous
Diaosrin and mass spec results.
In conclusion, we did not ﬁnd a signiﬁcant association
betweenvitaminDlevelsandthyroidnodules,thyroidcancer
in remission, and active thyroid cancer. This is diﬀerent
than studies looking at other solid tumors and warrants
further investigation. We also found the overall prevalence
of vitamin D deﬁciency to be higher than expected for
the general healthy population, which also needs to be
studied further in a larger population that controls for
issues known to aﬀect vitamin D such as ethnicity, BMI,International Journal of Endocrinology 7
season of measurement, autoimmunity, and vitamin D
supplementation.
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